The estimated Net Worth of Luca Benatti is at least 470 千$ dollars as of 14 May 2019. Luca Benatti owns over 1,200 units of Intercept Pharmaceuticals Inc stock worth over 143,564$ and over the last 10 years he sold ICPT stock worth over 0$. In addition, he makes 326,356$ as Independent Director at Intercept Pharmaceuticals Inc.
Sign up
Luca Benatti ICPT stock SEC Form 4 insiders trading
Luca has made over 2 trades of the Intercept Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,200 units of ICPT stock worth 100,200$ on 14 May 2019.
The largest trade he's ever made was buying 1,200 units of Intercept Pharmaceuticals Inc stock on 14 May 2019 worth over 100,200$. On average, Luca trades about 143 units every 115 days since 2014. As of 14 May 2019 he still owns at least 7,556 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Luca Benatti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Luca Benatti biography
Dr. Luca Benatti Ph.D. serves as Independent Director of the Company. Dr. Benatti has over 25 years of experience in the pharmaceutical and biotechnology industries. Since June 2012, Dr. Benatti has served as the Chief Executive Officer and a director of EryDel S.p.A., a private biotechnology company focused on rare diseases. From 1998 until May 2012, Dr. Benatti was Chief Executive Officer of Newron Pharmaceuticals S.p.A., a publicly traded biopharmaceutical company that Dr. Benatti co-founded. Under Dr. Benatti’s leadership, Newron developed a pipeline of potential therapies, with its most advanced compound, Xadago, approved for the treatment of Parkinson’s disease in various jurisdictions, and undertook significant business development activities. From 1985 to 1998, Dr. Benatti held various research and development positions at Pharmacia & Upjohn and its predecessor companies. Dr. Benatti has authored several scientific publications and holds a number of patents. Dr. Benatti currently serves as a director of Newron Pharmaceuticals S.p.A. Dr. Benatti also serves as chairman of Italian Angels for Biotech, a member of the Advisory Board of the Sofinnova Telethon Fund, a member of the Strategic Advisory Board of Zambon, a member of the Board of Assobiotec, the Italian Biotech Association, and a member of the jury of Open Accelerator and of the European Biotechnica Award. Dr. Benatti graduated from and performed his post-doctoral training at the Milano Genetics Institute.
What is the salary of Luca Benatti?
As the Independent Director of Intercept Pharmaceuticals Inc, the total compensation of Luca Benatti at Intercept Pharmaceuticals Inc is 326,356$. There are 14 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of 6,615,780$.
How old is Luca Benatti?
Luca Benatti is 59, he's been the Independent Director of Intercept Pharmaceuticals Inc since 2014. There are 4 older and 19 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
What's Luca Benatti's mailing address?
Luca's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 305 MADISON AVENUE, MORRISTOWN, NJ, 07960.
Insiders trading at Intercept Pharmaceuticals Inc
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over 1,530,243,701$ worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth 77,118,364$ . The most active insiders traders include Srinivas Akkaraju、Jonathan Silverstein、Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of 1,114,673$. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth 5,017,290$.
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
What does Intercept Pharmaceuticals Inc's logo look like?
Complete history of Luca Benatti stock trades at Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc executives and stock owners
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mark Pruzanski,
President, Chief Executive Officer, Director -
Jerome Durso,
Chief Operating Officer -
Ryan Sullivan,
General Counsel, Secretary -
Richard Kim,
President, U.S. Commercial & Strategic Marketing -
Sandip Kapadia,
Chief Financial Officer, Treasurer -
Gail Cawkwell,
Senior Vice President - Medical Affairs, Safety & Pharmacovigilance -
Lisa Bright,
President, International -
David Ford,
Chief Human Resource Officer -
Dr. Mark Pruzanski M.D.,
Founder, Advisor & Director -
Jerome B. Durso,
Pres, CEO & Director -
Paolo Fundaro,
Independent Chairman of the Board -
Gino Santini,
Lead Independent Director -
Glenn Sblendorio,
Independent Director -
Daniel Welch,
Independent Director -
Daniel Bradbury,
Independent Director -
Luca Benatti,
Independent Director -
Nancy Miller-Rich,
Independent Director -
Keith Gottesdiener,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Jason Campagna,
Chief Medical Officer -
Christian Weyer,
Executive Vice President - Research & Development -
Linda M. Richardson,
Exec. VP & Chief Commercial Officer -
Jared M. Freedberg J.D.,
Gen. Counsel -
Lisa M. DeFrancesco,
Sr. VP of Corp. Affairs & Investor Relations -
Rocco Venezia,
Chief Accounting Officer & Treasurer -
Bryan Ball,
Chief Quality Officer & Sr. VP of Operations -
Andrew Saik,
Chief Financial Officer -
Barbara Gayle Duncan,
Chief Financial Officer -
Rachel Mc Minn,
Chief Strategy Officer -
David Shapiro,
Chief Medical Officer -
Linda M Richardson,
EVP & Chief Commercial Officer -
S.P.A. Genextra,
-
M Michelle Berrey,
President, R&D and CMO -
Daniel Paul Regan,
Chief Commerical Officer -
Jonathan Silverstein,
Director -
Advisors Llc Orbi Med Capit...,
-
Lorenzo Tallarigo,
Director -
Klaus R Dr Veitinger,
Director -
Sanj K Patel,
Director -
Luciano Adorini,
Chief Scientific Officer -
Nicole Williams,
Director -
Francesco Micheli,
-
Bryan Ball,
Chief Qual. Officer & SVP Ops. -
Rocco Venezia,
Chief Accounting Officer -
Dagmar Rosa Bjorkeson,
Director -
Lisa De Francesco,
SVP, IR & Corp. Affairs -
Jared Freedberg,
General Counsel